Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 2, 2015, Pages 211-217

  Vaduganathan, Muthiah ^a   Zemer Wassercug, Noa ^b,c   Rechavia, Eldad ^b,c   Lerman Shivek, Hila ^b,c,d   Perl, Leor ^b,c   Leshem Lev, Dorit ^b   Orvin, Katia ^b,c   Kornowski, Ran ^b,c   Lev, Eli I ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiplatelet; Percutaneous coronary intervention; Platelet function; Ticagrelor

Indexed keywords

PURINERGIC P2Y12 RECEPTOR; THIAZOLE ORANGE; TICAGRELOR; ADENOSINE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; THROMBOCYTE; TREATMENT OUTCOME; ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; BLOOD; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BLOOD PLATELETS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TIME FACTORS;

EID: 84931561522     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1178-6     Document Type: Article

References (32)

1. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58(5):467–473. doi:10.1016/j.jacc.2011.04.017
2. Michelson AD, Frelinger AL III, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, Investigators T-T (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30(14):1753–1763. doi:10.1093/eurheartj/ehp159
3. Parguina AF, Grigorian-Shamajian L, Agra RM, Teijeira-Fernandez E, Rosa I, Alonso J, Vinuela-Roldan JE, Seoane A, Gonzalez-Juanatey JR, Garcia A (2010) Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 5(10):e13404. doi:10.1371/journal.pone.0013404
4. Robinson MS, Mackie IJ, Khair K, Liesner R, Goodall AH, Savidge GF, Machin SJ, Harrison P (1998) Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 100(2):351–357
5. Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon AP, Saleem A (2004) Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 44(10):2091–2093. doi:10.1016/j.jacc.2004.05.033
6. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5(3):490–496. doi:10.1111/j.1538-7836.2007.02387.x
7. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52(9):743–749. doi:10.1016/j.jacc.2008.05.031
8. Perl L, Lerman-Shivek H, Rechavia E, Vaduganathan M, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Codner P, Bental T, Battler A, Kornowski R, Lev EI (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517. doi:10.1016/j.jacc.2013.07.110
9. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606. doi:10.1016/j.jacc.2013.01.024
10. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60(3):193–199. doi:10.1016/j.jacc.2012.03.050
11. Laine M, Frere C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O, Helal O, Paganelli F, Dignat-George F, Bonello L (2013) Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost 111(2). doi:10.1160/TH13-05-0384
12. Perl L, Zemer-Wassercug N, Rechavia E, Vaduganathan M, Orvin K, Weissler-Snir A, Lerman-Shivek H, Kornowski R, Lev EI (2014) Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction. J Thromb Thrombolysis. doi:10.1007/s11239-014-1119-9
13. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057. doi:10.1056/NEJMoa0904327
14. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V (2006) Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28(5):315–322. doi:10.1358/mf.2006.28.5.990205
15. Toth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96(6):781–788
16. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet R (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919–933. doi:10.1016/j.jacc.2010.04.047
17. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124(10):1132–1137. doi:10.1161/CIRCULATIONAHA.111.029165
18. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M, Group PHES (2013) Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 34(3):220–228. doi:10.1093/eurheartj/ehs149
19. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK, Group PS (2013) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 128(10):1055–1065. doi:10.1161/CIRCULATIONAHA.113.002589
20. Levin LA, Wallentin L, Bernfort L, Andersson D, Storey RF, Bergstrom G, Lamm CJ, Janzon M, Kaul P (2013) Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value Health 16(4):574–580. doi:10.1016/j.jval.2013.01.013
21. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 32(23):2933–2944. doi:10.1093/eurheartj/ehr422
22. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L, Group PS (2012) Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 5(5):680–688. doi:10.1161/CIRCOUTCOMES.111.964395
23. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L, PS Group (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 35(23):1541–1550. doi:10.1093/eurheartj/ehu075
24. Deharo P, Pankert M, Bonnet G, Quilici J, Bassez C, Morange P, Alessi MC, Bonnet JL, Cuisset T (2014) Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. Int J Cardiol. doi:10.1016/j.ijcard.2014.07.228
25. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC, P Investigators (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749):1320–1328. doi:10.1016/S0140-6736(10)61274-3
26. Serebruany VL (2010) Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology 117(3):231–233. doi:10.1159/000322789
27. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 162(1):160–165. doi:10.1016/j.ahj.2010.11.025
28. Palmerini T, Dangas G, Mehran R, Caixeta A, Genereux P, Fahy MP, Xu K, Cristea E, Lansky AJ, Stone GW (2011) Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ Cardiovasc Interv 4(6):577–584. doi:10.1161/CIRCINTERVENTIONS.111.963884
29. Hirsh J, Glynn MF, Mustard JF (1968) The effect of platelet age on platelet adherence to collagen. J Clin Investig 47(3):466–473. doi:10.1172/JCI105743
30. Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Investig 48(6):1083–1087. doi:10.1172/JCI106064
31. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS (1992) The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 98(6):637–646
32. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25):2577–2585. doi:10.1161/CIRCULATIONAHA.109.912550